Predict your next investment

Venture Capital
emeraldmanagers.com

See what CB Insights has to offer

Investments

16

About Emerald Development Managers

Emerald Development Managers is an early stage/growth equity investor. The firm has a distinct and highly-disciplined, long-term investment strategy to drive the creation of valuable companies by providing investment capital, guidance, and hands-on experience in the development, ownership and operation of early stage companies and projects. To facilitate this drive to value, the firm seeks to partner with highly-motivated and creative management teams to bring their concepts to life.

Emerald Development Managers Headquarter Location

909 3rd Ave Floor 15

New York, New York, 10022,

United States

212-317-2250

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Emerald Development Managers News

Babson Diagnostics Raises $31M in Series B Funding

Jul 4, 2021

Babson Diagnostics , an Austin TX-based medical technology company, raised $31M in Series B funding. The round was led by Emerald Development Managers with participation from Healthineers, Prism Ventures, and Lago Consulting Group. The company intends to use the funds to expand its laboratory and ecosystem infrastructure, finalize its blood testing solution development, and grow its sales and marketing teams. In conjunction with the funding, Neil Cohen, founder and chairman of Emerald Development Managers, will join Babson’s board of directors. Originally incubated at Siemens Healthineers and using an innovative collection device developed in collaboration with BD (Becton, Dickinson and Company), Babson has advanced a technological ecosystem that reimagines the entire diagnostic blood testing process. Innovations in collection, sample handling, and analysis enable the company to use small capillary samples to produce a full range of diagnostic test. Led by and David Stein, Ph.D., chief executive officer, Eric Olson, Babson’s founder, chairman, and chief operating officer, Babson plans to deploy its proprietary diagnostics ecosystem at pharmacies and other retail locations throughout the country. FinSMEs

Emerald Development Managers Investments

16 Investments

Emerald Development Managers has made 16 investments. Their latest investment was in TrueFort as part of their Series B on September 9, 2021.

CBI Logo

Emerald Development Managers Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/8/2021

Series B

TrueFort

$30M

No

9

6/29/2021

Series B

Babson Diagnostics

$31M

Yes

1

3/16/2021

Series B

Cyware Labs

$30M

No

2

8/17/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2020

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/8/2021

6/29/2021

3/16/2021

8/17/2020

4/27/2020

Round

Series B

Series B

Series B

Series A

Series A - II

Company

TrueFort

Babson Diagnostics

Cyware Labs

Subscribe to see more

Subscribe to see more

Amount

$30M

$31M

$30M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

1

2

10

10

Emerald Development Managers Team

2 Team Members

Emerald Development Managers has 2 team members, including current Managing Director, Stephen Case.

Name

Work History

Title

Status

Stephen Case

Managing Director

Current

Charles T Collins

Managing Director

Current

Name

Stephen Case

Charles T Collins

Work History

Title

Managing Director

Managing Director

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.